anaptysbio
reports
positive
topline
data
gallop
phase
clinical
trial
imsidolimab
generalized
pustular
psoriasis
gpp
patients
achieved
primary
endpoint
improvement
clinical
global
impression
scale
cgi
day
rapid
reduction
skin
pustules
day
clearance
day
fda
meeting
anticipated
outline
registration
path
imsidolimab
treatment
gpp
accordance
orphan
drug
designation
obtained
july
palmoplantar
pustulosis
ppp
phase
poplar
trial
enrollment
completed
data
anticipated
worldwide
registry
gpp
ppp
patients
named
radiance
initiated
improve
understanding
patient
journey
support
enrollment
future
trials
initiation
imsidolimab
phase
trials
skin
toxicity
ichthyosis
anticipated
san
diego
globe
newswire
anaptysbio
nasdaq
anab
biotechnology
company
developing
antibody
product
candidates
focused
emerging
immune
control
mechanisms
applicable
inflammation
indications
today
announced
positive
topline
data
interim
analysis
phase
clinical
trial
imsidolimab
treatment
generalized
pustular
psoriasis
gpp
also
known
gallop
trial
gpp
chronic
rare
inflammatory
disease
approved
therapies
encouraged
rapid
onset
overall
safety
promising
efficacy
profile
demonstrated
date
imsidolimab
treatment
patients
suffering
gpp
said
paul
lizzul
chief
medical
officer
anaptysbio
look
forward
engaging
regulatory
authorities
progress
imsidolimab
phase
offer
potential
therapeutic
intervention
patients
high
unmet
medical
gpp
disease
seriously
debilitates
patient
lives
approved
therapies
said
johann
gudjonsson
associate
professor
dermatology
university
michigan
efficacy
safety
demonstrated
trial
validates
potential
receptor
inhibition
helping
gpp
patients
look
forward
advancement
imsidolimab
treatment
gpp
inflammatory
conditions
target
pathway
may
play
important
study
data
key
data
available
date
patients
enrolled
gallop
trial
follows
mean
baseline
value
modified
japanese
dermatology
association
severity
index
total
score
table
body
surface
area
covered
erythema
pustules
serum
protein
crp
mg
patients
average
years
age
female
diagnosed
gpp
years
six
patients
treated
imsidolimab
monotherapy
achieved
primary
endpoint
improvement
cgi
scale
day
two
patients
considered
met
primary
endpoint
dropped
trial
prior
day
score
incorporates
dermatological
systemic
aspects
gpp
decreased
average
day
day
erythema
skin
pustules
clinically
defines
gpp
decreased
day
day
serum
crp
indicator
systemic
inflammation
normal
less
mg
l
patients
achieving
primary
endpoint
day
genotypic
testing
indicated
homozygous
alleles
patients
believe
suggests
imsidolimab
broadly
applicable
pustular
diseases
irrespective
genetic
drivers
antibodies
detected
day
patient
endpoint
baseline
day
relative
baseline
day
relative
baseline
improvement
cgi
n
patients
patients
erythema
skin
pustules
body
surface
area
table
key
endpoints
day
day
relative
baseline
imsidolimab
generally
adverse
events
mild
moderate
severity
resolved
without
sequelae
infusion
injection
site
reactions
observed
one
patient
dropped
trial
due
diagnosis
staphylococcal
aureus
bacteremia
first
week
serious
adverse
event
deemed
possibly
patient
symptomatic
prior
dosing
prior
medical
history
bacteremia
common
comorbidity
gpp
company
believe
event
likely
attributable
imsidolimab
another
patient
dropped
study
day
due
investigator
reported
inadequate
efficacy
one
patient
contracted
course
trial
mild
unrelated
imsidolimab
lead
study
discontinuation
meeting
based
upon
data
available
patients
enrolled
gallop
trial
anticipated
july
fda
granted
orphan
drug
designation
imsidolimab
treatment
gpp
based
upon
gallop
clinical
data
company
plans
report
full
data
gallop
trial
medical
conference
gallop
phase
trial
design
upon
review
day
data
patients
enrolled
gallop
trial
company
decided
curtail
enrollment
proceed
preparations
meeting
fda
patients
include
patients
reported
september
patients
completed
dosing
period
patients
anticipated
complete
week
dosing
period
patients
dropped
date
patients
screened
among
sites
located
united
states
europe
patients
washed
prior
therapy
concomitant
therapy
permitted
trial
rescue
therapy
required
patients
enrolled
trial
key
inclusion
criteria
include
active
ongoing
gpp
disease
minimum
score
least
body
surface
area
covered
active
pustules
erythema
key
exclusion
criteria
included
concomitant
dermatological
conditions
infection
patients
treated
intravenous
induction
dose
imsidolimab
day
followed
monthly
subcutaneous
doses
days
primary
endpoint
trial
clinical
response
cgi
scale
day
day
without
rescue
therapy
baseline
clinical
assessments
conducted
patient
day
prior
imsidolimab
dosing
missing
data
points
imputed
using
forward
locf
methodology
addition
gpp
company
plans
advance
development
imsidolimab
multiple
inflammatory
indications
associated
pathway
dysregulation
enrollment
completed
poplar
randomized
phase
trial
imsidolimab
ppp
data
anticipated
company
also
plans
initiate
worldwide
patient
registry
called
radiance
patients
diagnosed
gpp
ppp
anticipated
improve
understanding
patient
journey
support
future
clinical
trial
enrollment
addition
clinical
development
imsidolimab
expanded
two
additional
indications
skin
toxicity
ichthyosis
phase
trials
expected
initiated
gpp
gpp
rare
chronic
inflammatory
disease
currently
approved
therapies
typically
diagnosed
age
patients
die
complications
bacteremia
sepsis
acute
respiratory
distress
syndrome
cardiac
failure
patients
treated
systemic
agents
including
cyclosporine
methotrexate
corticosteroids
retinoids
biologics
often
tapered
discontinued
due
lack
efficacy
toxicity
primary
market
research
including
code
claims
indicate
least
gpp
patients
united
states
regularly
treated
dermatologists
gpp
known
associated
excess
signaling
receptor
caused
genetic
mutations
environmental
factors
imsidolimab
imsidolimab
previously
known
antibody
inhibits
function
anaptysbio
plans
initially
develop
potential
therapy
patients
suffering
generalized
pustular
psoriasis
gpp
palmoplantar
pustulosis
ppp
skin
toxicity
ichthyosis
anaptysbio
previously
presented
data
phase
clinical
trial
demonstrated
safety
pharmacokinetics
pharmacodynamic
properties
supported
advancement
imsidolimab
phase
studies
anaptysbio
anaptysbio
biotechnology
company
developing
antibody
product
candidates
focused
emerging
immune
control
mechanisms
applicable
inflammation
indications
company
proprietary
pipeline
includes
antibody
imsidolimab
previously
referred
treatment
rare
inflammatory
diseases
including
generalized
pustular
psoriasis
gpp
palmoplantar
pustulosis
ppp
skin
toxicities
ichthyosis
antibody
etokimab
previously
referred
treatment
chronic
rhinosinusitis
nasal
polyps
crswnp
eosinophilic
asthma
agonist
program
treatment
certain
autoimmune
diseases
immune
checkpoint
receptors
insufficiently
activated
btla
modulator
program
broadly
applicable
human
inflammatory
diseases
associated
lymphoid
myeloid
immune
cell
dysregulation
anaptysbio
antibody
pipeline
developed
using
proprietary
somatic
hypermutation
shm
platform
uses
vitro
shm
antibody
discovery
designed
replicate
key
features
human
immune
system
overcome
limitations
competing
antibody
discovery
technologies
anaptysbio
also
developed
multiple
therapeutic
antibodies
collaboration
glaxosmithkline
including
antagonist
antibody
dostarlimab
antagonist
antibody
cobolimab
antagonist
antibody
inflammation
collaboration
squibb
including
checkpoint
agonist
antibody
currently
clinical
development
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
including
limited
timing
release
data
imsidolimab
phase
clinical
trial
ppp
timing
fda
meeting
imsidolimab
gpp
timing
initiation
worldwide
registry
gpp
ppp
timing
initiation
clinical
trials
skin
toxicity
ichthyosis
imsidolimab
timing
full
data
report
gallop
trial
medical
conference
statements
including
words
plan
continue
expect
ongoing
statements
future
tense
statements
statements
involve
risks
uncertainties
well
assumptions
fully
materialize
prove
incorrect
could
cause
results
differ
materially
expressed
implied
statements
statements
subject
risks
uncertainties
may
cause
company
actual
activities
results
differ
significantly
expressed
statement
including
risks
uncertainties
related
company
ability
advance
product
candidates
obtain
regulatory
approval
ultimately
commercialize
product
candidates
timing
results
preclinical
clinical
trials
company
ability
fund
development
activities
achieve
development
goals
company
ability
protect
intellectual
property
risks
uncertainties
described
heading
risk
factors
documents
company
files
time
time
securities
exchange
commission
statements
speak
date
press
release
company
undertakes
obligation
revise
update
statements
reflect
events
circumstances
date
hereof
contacts
dennis
mulroy
anaptysbio
dmulroy
